Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
XG
Exagen Inc. Common Stock
XGN
Mkt Cap
$187.1M
Volume
940.86K
Next Earnings
November 3rd
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
XG
XGN
XG
Exagen Inc. Common Stock
XGN
News
·
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
Mkt Cap
$207.4M
Volume
940.86K
Next Earnings
November 3rd
Chart
Financials
Earnings
News
About
Insider
Filings
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
Exagen Inc. (Nasdaq: XGN), a provider of autoimmune diagnostics, announced select preliminary unaudited financial results for Q4 and full year 2025 that are in line with prior guidance. The company will release complete financial results on March 10, 2026, followed by a conference call with leadership.
GlobeNewswire Inc. · Feb 24, 2026
Exagen Inc. Announces Select Preliminary 2025 Financial Results
Exagen Inc. (Nasdaq: XGN) announced preliminary 2025 financial results showing record full-year revenue of $66M-$67M, representing 19-20% year-over-year growth. The company achieved AVISE CTD test volume growth of 11% and trailing 12-month average selling price expansion of at least $30 compared to 2024. Year-end cash position strengthened to $32M, up $10M from 2024. CEO John Aballi highlighted strong execution across teams and recent platform enhancements despite ASP headwinds in the second half of the year.
GlobeNewswire Inc. · Jan 11, 2026
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
Exagen Inc., a leading autoimmune diagnostics company, announced participation in two upcoming investor conferences in November 2025, highlighting its commitment to showcasing its innovative autoimmune testing solutions.
GlobeNewswire Inc. · Nov 11, 2025
Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Zacks Investment Research · Jun 13, 2024
Time to Play 5 Top-Ranked Stocks With Rising P/E?
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Exagen (XGN), Health Catalyst (HCAT), CLEAR Secure (YOU) and Applied DNA Sciences (APDN).
Zacks Investment Research · Jun 10, 2024
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
Exagen (XGN) delivered earnings and revenue surprises of 52.50% and 9.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 13, 2024
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
Quanterix (QTRX) delivered earnings and revenue surprises of 21.21% and 1.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 7, 2024
Exagen to Announce First Quarter 2024 Results on May 13, 2024
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:30 AM ET (5:30 AM PT).
GlobeNewswire Inc. · Apr 30, 2024
Exagen Inc. Announces Changes to the Board of Directors
CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors.
GlobeNewswire Inc. · Apr 26, 2024
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
Exagen Inc. (XGN) delivered earnings and revenue surprises of 24.39% and 20.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · Mar 18, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
XG
XGN
Exagen Inc. Common Stock
Buy
Sell
Market
Limit
Soon
XGN
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any XGN yet.
Related Tickers
Earnings